Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Residual platelet function assessed by 20 µM ADP-induced aggregation (top) and flow cytometry analysis of fibrinogen-platelet binding (bottom) in 25 patients who received tirofiban followed by abciximab and in 10 patients who received only abciximab. Results are expressed as mean ± SEM percent of baseline aggregation. Administration of abciximab to tirofiban-treated patients caused a significant decrease in platelet function. Open square = tirofiban-abciximab group; solid circle = abciximab control group. Abx = abciximab; Maint = maintenance; Tir = tirofiban.
|
